|Description||MK-0893 is a potent, selective glucagon receptor antagonist with high binding affinity with IC(50) of 6.6 nM and functional cAMP activity with IC(50) of 15.7 nM. It is selective for glucagon receptor relative to other family B GPCRs and is > 200 fold selectivity for GIPR, PAC1, GLP-1R, VPAC1 and VPAC2. It blunted glucagon-induced glucose elevation in hGCGR mice and rhesus monkeys. It may be a potential oral treatment for type 2 diabetes. It was selected for further preclinical and clinical evaluations.|
|Synonyms||b-Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]-;Merk Glucagon antagonist;N-[4-[(1S)-1-[3-(3,5-Dichlorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]-beta-alanine;(S)-3-(4-(1-(3-(3,5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl)ethyl)benzamido)propanoic acid|
|Solubility||10 mM in DMSO|
|Application||MK-0893 may be a potential oral treatment for type 2 diabetes.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Boiling Point||814.0±65.0 °C | Condition: Press: 760 Torr|
|Density||1.33±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
Liraglutide is the long-acting analogue of glucagon-like peptide-1 (GLP-1) receptor which could protect b-cells from apoptosis under conditions associated with ...
Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist (EC50= 0.06 nM) under investigation for treatment of type 2 diabetes.
Glucagon receptor antagonists 1
Glucagon receptor antagonists-1 is a highly potent glucagon receptor antagonist, which is activated by glucagon and is a member of the class B G-protein coupled...
glucagon receptor antagonists-4
glucagon receptor antagonists-4 is a potent glucagon receptor antagonist with great oral bioavailability in vivo.
Exendin (9-39) is a specific and competitive glucagon-like peptide-1receptor antagonist (Kd = 1.7 nM at cloned human GLP-1 receptors). Exendin (9-39) inhibits i...
Adomeglivant has been found to be a glucagon receptor antagonist that could probably be effective for both type-I and type-II diabetes mellitus.
glucagon receptor antagonists-3
glucagon receptor antagonists-3 is a highly potent antagonist of glucagon receptor .
CP-320626, a carboxamide derivative, is a potent glycogen phosphorylase inhibitor and a possible target for type 2 diabetes therapy. CP-320626 is also a potent ...
Ingliforib, with antihyperglycemic and cardioprotective properties, inhibits glycogen phosphorylase.
GRA Ex-25 is an orally active human glucagon receptor antagonist in a transgenic murine pharmacodynamic model, with IC50 of 56 and 55 nM for rat and human gluca...
BAY-27-9955 is a specific glucagon receptor antagonist.
LGD-6972 is an orally bioavailable small molecule glucagon receptor antagonist being developed as an adjunct to diet and exercise to improve glycemic control in...
MK-0893 is a selective glucagon receptor antagonist. It can block glucagon binding to the human GCGR and antagonize glucagon-induced intracellular accumulation ...
MK-0893 is a potent, selective glucagon receptor antagonist with high binding affinity with IC(50) of 6.6 nM and functional cAMP activity with IC(50) of 15.7 nM...
glucagon receptor antagonists-2
glucagon receptor antagonists-2 is a highly potent antagonist of glucagon receptor .
Exenatide acetate is a potent peptide agonist of the glucagon-like peptide 1 (GLP-1) receptor with Ki value of 136 pM. It is a 39 amino acid peptide, which incr...